Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|May 11, 2016
eAccess Technology in Specialty Pharmacy
Author(s)Lauren Santye, Assistant Editor
Gregory R. Morris, chief commercial officer at VirMedica, discusses how eAccess can benefit patients and providers.
Advertisement
Gregory R. Morris, chief commercial officer at VirMedica, discusses how eAccess can benefit patients and providers.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Pharmacy Times
1
Armored CAR T-Cell Therapy Produces Durable Complete Response in Pediatric Solid Tumors
2
Expert Q&A: Pharmacists Address Pneumococcal Vaccine Hesitancy and Screening Complexity in Transitions of Care
3
Not So Rare After All: Pharmacists Weigh In on Diagnosing and Managing ATTR-CM
4
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
5